Upfront low‐dose ponatinib (15 mg/day) for multi‐TKI resistant chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Hematological Oncology"
DOI: 10.1002/hon.2517
Abstract: There is currently little information on the upfront use of low‐dose ponatinib (15 mg once‐daily) for patients with chronic phase chronic myeloid leukemia. And yet, the concept carries immediate clinical relevance because of the association… read more here.
Keywords: low dose; myeloid leukemia; dose ponatinib; chronic myeloid ... See more keywords